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Abstract
Background: Non-viral-based gene modification of adult stem cells with endothelial nitric oxide synthase (eNOS)
may enhance production of nitric oxide and promote angiogenesis. Nitric oxide (NO) derived from endothelial cells
is a pleiotropic diffusible gas with positive effects on maintaining vascular tone and promoting wound healing and
angiogenesis. Adult stem cells may enhance angiogenesis through expression of bioactive molecules, and their genetic
modification to express eNOS may promote NO production and subsequent cellular responses.
Methods: Rat bone marrow-derived mesenchymal stem cells (rBMSCs) were transfected with a minicircle DNA vector
expressing either green fluorescent protein (GFP) or eNOS. Transfected cells were analysed for eNOS expression and
NO production and for their ability to form in vitro capillary tubules and cell migration. Transcriptional activity of
angiogenesis-associated genes, CD31, VEGF-A, PDGFRα, FGF2, and FGFR2, were analysed by quantitative polymerase
chain reaction.
Results: Minicircle vectors expressing GFP (MC-GFP) were used to transfect HEK293T cells and rBMSCs, and were
compared to a larger parental vector (P-GFP). MC-GFP showed significantly higher transfection in HEK293T cells
(55.51 ± 3.3 %) and in rBMSC (18.65 ± 1.05 %) compared to P-GFP in HEK293T cells (43.4 ± 4.9 %) and rBMSC
(15.21 ± 0.22 %). MC-eNOS vectors showed higher transfection efficiency (21 ± 3 %) compared to P-eNOS (9 ± 1 %)
and also generated higher NO levels. In vitro capillary tubule formation assays showed both MC-eNOS and P-
eNOS gene-modified rBMSCs formed longer (14.66 ± 0.55 mm and 13.58 ± 0.68 mm, respectively) and a greater
number of tubules (56.33 ± 3.51 and 51 ± 4, respectively) compared to controls, which was reduced with the NOS
inhibitor L-NAME. In an in vitro wound healing assay, MC-eNOS transfected cells showed greater migration which
was also reversed by L-NAME treatment. Finally, gene expression analysis in MC-eNOS transfected cells showed
significant upregulation of the endothelial-specific marker CD31 and enhanced expression of VEGFA and FGF-2
and their corresponding receptors PDGFRα and FGFR2, respectively.
Conclusions: A novel eNOS-expressing minicircle vector can efficiently transfect rBMSCs and produce sufficient
NO to enhance in vitro models of capillary formation and cell migration with an accompanying upregulation of
CD31, angiogenic growth factor, and receptor gene expression.
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Background
Development of safe and efficient systems for gene
transfer is required for translation of gene-modified stem
cells into therapeutic applications. Conventional plasmid
DNA (pDNA)-based non-viral vectors contain bacterial
sequences and transcriptional units that may contribute
to an immune response against bacterial proteins
expressed from cryptic upstream eukaryotic expression
signals. Furthermore, changes in eukaryotic gene expres-
sion may be altered due to the antibiotic resistance
marker and immune responses to bacterial CpG se-
quences [1]. These prokaryotic DNA sequences present
in pDNA vectors may lower their biocompatibility and
safety. In clinical studies, un-methylated CpG motifs
induced inflammatory responses [2] and necrosis- or
apoptosis-mediated cell death in target cells, resulting in
short-lived transgene expression [3, 4]. Furthermore,
during the intracellular trafficking of pDNA, the bacter-
ial sequences of pDNA vectors are rapidly associated
with histone proteins, packing the sequences into a
dense heterochromatin structure. If these are spread into
the adjacent transgene in the vector, the sequences can be-
come inaccessible by transcription factors, leading to re-
duced transgene expression through silencing of the
eukaryotic promoter [5]. The removal of CpG islands by
cloning out, or elimination of non-essential sequences,
can reduce these undesirable responses but is time-
consuming and tedious.
Minicircle (MC) pDNA technology consists of super-
coiled DNA molecules for non-viral gene transfer, which
has neither a bacterial origin of replication nor an anti-
biotic resistance gene [6]. MCs can be generated in E. coli
ZYCY10P3S2T by attachment sites ((attP and attB), with
specific recombination mediated by the phage ΦC31 inte-
grase [1]. As a result of this recombination event between
attP and attB sites, MCs contain only a eukaryotic expres-
sion cassette and the attR fragments are formed but are
devoid of bacterial backbone sequences. Absence of the
bacterial backbone sequences leads to a size reduction in
the MC relative to the parental pDNA which can enhance
in vitro transfection efficiency [7] and in vivo gene delivery
[8, 9]. Gene expression from non-viral episomal vectors
may also enhance persistence of transgene expression
without interrupting to the cellular genome [10].
Endothelial nitric oxide synthase (eNOS), also known
as NOS3, is expressed in endothelial cells [11], and is
responsible for generating nitric oxide (NO) which plays
an important role in vasculogenesis [12, 13]. NO pro-
duced from endothelial cells is important for maintain-
ing vascular integrity and may enhance vasculogenesis
through fibroblast growth factor (FGF) signalling [14].
Vascular endothelial growth factor (VEGF) is also induced
by the NO synthesis pathway [15] contributing to angio-
genesis. eNOS knockout mice (eNOS−/−) display impaired
vasculogenesis [16] and have also demonstrated dimin-
ished wound healing due to reduced VEGF-mediated mi-
gration of endothelial cells [17] and bone marrow
progenitor cells [18] to the sites of injury. eNOS-based
gene therapy approaches have shown restoration of
impaired angiogenesis in rats [19, 20] and promotion
of re-endothelialisation [21] in injured rabbits upon
adenovirus-mediated eNOS gene transfer.
Similar to endothelial progenitor cells, mesenchymal
stem cells (MSCs) also participate in post-natal angiogen-
esis [22], and vascular pericytes, which are crucial for
maintaining vascular integrity, share similar phenotypic
features with MSCs [23]. Exogenously administered,
MSCs form new capillaries and medium-sized arteries
[24] which are important properties of tissue regeneration
by MSCs [25]. MSCs can differentiate into endothelial
cells in vitro [26] and contribute to neovascularisation,
particularly during tissue ischaemia and tumour vascular-
isation [27]. In MSCs, VEGF-A binds with platelet-derived
growth factor receptor (PDGFR) to initiate VEGF-A/
PDGFR signalling and drive vasculogenesis, as opposed to
the VEGFR2 in endothelial cells, which is absent on MSCs
[28]. NO has been shown to upregulate PDGFRα receptor
expression in rat mesangial cells [29], and the induction of
tumour angiogenesis has been linked to the NO-induced
Notch signalling pathway in PDGFR-activated mouse gli-
oma cells [30]. FGF2 signalling also enhances vasculogen-
esis through promotion of NO production [31, 32]. eNOS
is the only NOS isoform absent in MSCs [13], and hence
eNOS-based genetic modification of MSCs may enhance
their therapeutic application. In this study, we describe a
novel non-viral MC vector to deliver the eNOS transgene
to MSCs with higher transfection efficiency than regular
plasmids. NO signalling in the gene-modified MSC pro-
motes capillary tube-like network formation and cell mo-
tility. Quantitative real time polymerase chain reaction
(PCR) data revealed that MC-mediated eNOS gene trans-
fer significantly upregulates endothelial-specific CD31
gene expression. Furthermore, NO upregulates the angio-
genic responsive genes VEGF-A and FGF2 and expression
of their corresponding receptors, PDGFRα and FGFR2.
Methods
Rat bone marrow-derived mesenchymal stem cell
isolation
All experiments involving animals were approved by the
Charles Sturt University animal ethics committee. MSCs
were isolated from the bone marrow of 8–12 week old
male Sprague–Dawley rats as previously described [33].
Tri-lineage differentiation of rat bone marrow-derived
mesenchymal stem cells
The ability of the isolated rat bone marrow-derived MSCs
(rBMSCs) (Passage 6) to differentiate to adipogenic,
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osteogenic and chondrogenic lineages was investigated.
To induce osteogenic differentiation, rBMSCs at 80–90 %
confluency were incubated in osteogenic-defined medium
(Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10 % fetal bovine serum (FBS), 10 mM beta-
glycerol phosphate, 10 nM dexamethasone and 0.2 mM
L-ascorbic acid 2-phosphate) for 11 days with medium
changed twice a week, as described previously [34]. Cells
were then fixed with 4 % paraformaldehyde and stained
with Alizarin Red S (pH 4.1) as described previously [35].
To induce adipogenic differentiation, rBMSCs at
80–90 % confluency were incubated in adipogenic-
defined medium (DMEM supplemented with 10 %
FBS, 10 μM indomethacin, 1 μM dexamethasone, 0.8 μM
insulin, 0.5 mM rosiglitazone) [36] for 1 week with
media changed twice. Adipogenic differentiation was
assessed by 0.18 % Oil Red O staining after fixing the
cells in 10 % neutral-buffered formalin (NBF) [35].
To induce chondrogenic differentiation, three-
dimensional pellet cultures of rBMSCs (2.5 × 105 cells)
were formed by centrifugation at 500 × g in 10 ml
conical-bottomed sterile tubes. The chondrogenic in-
duction medium consisted of DMEM supplemented
with 1 × ITS + 3 (Sigma), 1 × non-essential amino acids
(Sigma), 10 ng/ml transforming growth factor β (TGF-β3;
Peprotech), 100 nM dexamethasone, and 2 μM ascorbic
acid (Sigma) [37]. Pellet cultures were incubated in induc-
tion medium for 14 days with the medium changed every
second day with the lids of the tube loosened to facilitate
gas exchange. At day 14 the pellets were fixed in 10 %
NBF for 24 h, and the three-dimensional tissues were
processed and embedded in paraffin wax for microtome
processing. To assess chondrogenic differentiation, em-
bedded pellets were sectioned (5 μm slices) and stained
with 1 % Alcian blue to visualise glycosaminoglycan
accumulation.
The images for differentiated cells into all three
lineages were captured by a colour camera (Nikon
Digital Sight Ds-Fi2) attached to a Nikon Eclipse-Ti-U
microscope (Nikon).
Production of minicircle plasmid DNA-expressing eNOS
To construct an eNOS expressing minicircle vector,
a codon optimized human eNOS cDNA sequence
(3633 bp) was cloned into the minicircle parental
plasmid consisting of expression cassette CMV–MCS–
EF1α–GFP–SV40–PolyA (P-GFP) (System Biosciences,
Mountain View, CA, USA). This cloning strategy allowed
removal of the EF1α–GFP portion from the final construct
(P-eNOS).
The minicircle DNA plasmids expressing eNOS and
GFP were produced according to the manufacturer’s
instructions (System Biosciences). Briefly, E. coli
ZYCY10P3S2T cells were transformed with P-GFP and
P-eNOS. Following this, single colonies were grown in 2
ml LB (luria broth) media containing 50 μg/ml kanamy-
cin for 1 h at 30 °C with vigorous shaking at 200 rpm.
Next, 50 μl of the starter culture was then used to inocu-
late 200 ml fresh terrific broth (TB; Sigma) in a 1 litre
flask with 50 μg/ml kanamycin followed by incubation at
30 °C for 17 h with constant shaking at 200 rpm. Mini-
circle induction medium consisting of 200 ml LB (luria
broth), 8 ml 1 N NaOH and 200 μl 20 % L-arabinose
was combined with the TB bacterial culture and incu-
bated for a further 4 h at 30 °C with constant shaking
at 200 rpm. Minicircle plasmid DNA (MC-eNOS and
MC-GFP) was isolated using a Genomed Jetstar 2.0
midi kit according to the manufacturer’s instructions
(Genomed, Germany) and treated with plasmid-safe
ATP-dependent DNase (Epicentre, USA) to remove
bacterial genomic DNA contamination. eNOS- and
GFP-containing minicircles were designated as MC-
eNOS and MC-GFP, respectively.
Cell culture and transfection
Human embryonic kidney (HEK293T) cells and rBMSCs
were maintained in DMEM (Sigma) supplemented with
10 % (v/v) FBS (Sigma), 1 % (v/v) L-glutamate (Sigma)
and 1 % (v/v) penicillin/streptomycin antibiotics mix
(Sigma). Cells were transfected with the plasmids (P-GFP,
MC-GFP, P-eNOS and MC-eNOS) using Lipofectamine
2000 reagent (Life technologies, USA) following the
manufacturer’s instructions. GFP expression was assessed
by fluorescence microscopy at 24 and 48 h after transfec-
tion, and flow cytometry analysis (Gallios Instrument,
Beckmann).
Immunocytochemistry
Immunocytochemical detection of eNOS expression in P-
eNOS and MC-eNOS transfected HEK293T and rBMSCs
was performed as follows. Briefly, cells were fixed in 4 %
paraformaldehyde for 20 min at room temperature,
treated with 0.1% Triton-X100 in phosphate-buffered
saline (PBS) for 10 min, and blocked in a 10 % FBS in
PBS solution for 30 min at room temperature. This
was followed by a 2-h incubation with a primary
mouse monoclonal anti-eNOS antibody (BD Bio-
science), and subsequently with an anti-mouse IgG
secondary antibody conjugated with Alexa 488 (Cell
Signalling Technology) for 1 h followed by DAPI (nu-
clear stain) and phalloidin-TRITC (cytoskeleton stain)
(Sigma). eNOS-positive cells were counted by fluores-
cence microscopy in five randomly selected fields per
well in three independent experiments and 500–1000
cells were counted in total; the percentage of eNOS
positivity was calculated from the total nuclear
stained cells.
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Nitric oxide detection
Nitric oxide released from P-eNOS and MC-eNOS
transfected cells in cell supernatants was measured using
the griess reagent (Promega) following the manufac-
turer’s instructions. NO was also directly detected in
transfected cells using a specific fluorescent NO indicator,
4,5-diaminofluorescein diacetate (DAF-2DA; Cayman
chemicals, USA), as described previously [13, 38]. Cells
were grown to confluence on a 12-well plate and incu-
bated for 30 min with 1 μM DAF-2DA. Subsequently, cells
were washed with fresh PBS and viewed by a fluorescence
microscope.
In vitro angiogenesis
In vitro capillary formation was performed as described
previously [39]. Briefly, Geltrex™ (Life technologies) was
thawed on ice overnight and applied evenly over each
well (50 μl) of a 96-well plate and incubated for 30 min
at 37 °C allowing polymerisation. Transfected rBMSCs
or control cells were seeded at 20,000 cells per well and
grown in 100 μl angiogenic induction medium (DMEM
(Sigma), 1.5 % FBS, 1 % (v/v) L-glutamate (Sigma) and 1
% (v/v) penicillin/streptomycin (Sigma)) and incubated
at 37 °C for 5 h. The capillary network was fixed with
4 % paraformaldehyde and visualized by staining with
DAPI and Phalloidin (Sigma). The efficiency of in vitro
tubule formation was evaluated by measuring the num-
ber of nodes and length of the tubules as described
previously [13].
In vitro scratch wound healing assay
The effect of nitric oxide on cell migration was assessed
using an in vitro scratch wound healing assay as de-
scribed previously [37]. Briefly, HEK293T cells and
rBMSCs were transfected with P-eNOS, MC-eNOS, P-
GFP and MC-GFP in 6-well tissue culture plates. Next,
48 h following the transfection when the cells reached
100 % confluence, scratch wounds were made using a
sterile 200 μl pipette tip and the boundaries were
marked. The cells were then cultured with 2 ml fresh
DMEM supplemented with 10 % (v/v) FBS (Sigma), 1 %
(v/v), L-glutamate (Sigma), and 1 % (v/v) penicillin/
streptomycin (Sigma). Phase-contrast microscopy images
were acquired at 0 and 1 h after scratches were cre-
ated for rBMSCs and after17 h for HEK293T cells.
Cell migration was measured at the indicated times
by measuring the distance from the initial boundary
edge to the boundary of the migrating cells, followed
by calculation of the percentage of wound closure as
follows: percentage of wound closure = (distance from
the boundary edge at 0 h – distance from the bound-
ary edge at 1 h or 17 h)/(distance from the boundary
edge at 0 h) × 100.
Gene expression by quantitative real time PCR
Total RNA from transfected and control cells was
isolated using the PureZol reagent (BioRad) according
to the manufacturer’s instructions and the concentra-
tion of isolated RNA was determined using a Nanodrop
spectrophotometer (Thermo Scientific) following treat-
ment with RQ1 RNase free DNase (Promega) to
remove contaminating DNA. Then, cDNA was synthe-
sized with 1 μg RNA using a High Capacity Reverse
Transcription Kit (Life technologies). The quantitative
real time PCR assays were performed on a BioRad
CFX96 Real-Time system (BioRad) using the SsoFast
EvaGreen Supermix (BioRad). Primers used for target
amplification are described in Table 1. Assays were
performed in triplicate, and target mRNA expression
was normalized to rat GAPDH mRNA levels using the
ΔCt method.
Western blot analysis
Transfected and control cells were washed with ice-cold
PBS (Sigma) twice, and lysates were prepared by
homogenization of cells in RIPA buffer (Sigma), follow-
ing mixing with 4 × NuPAGE LDS sample buffer (Life
technologies) and lysed by heating for 10 min at 70 °C.
Total proteins were separated by 4–12 % Bis-Tris
NuPAGE (Novex, Life technologies) and transferred to
PVDF membrane (Millipore). After blocking with odys-
sey blocking buffer (LI-COR) for 30 min at room
temperature, the membrane was incubated with primary
antibodies specific to eNOS (1:1000 dilution) and β-
actin (LI-COR; 1:1000 dilution) overnight at 4 °C.
The membrane was washed with 0.1 % tween in PBS
three times for 10 min each, incubated with donkey
Table 1 Primers used in this study
Target Forward Reverse Expected size Accession number
VEGF-A GGTGGACATCTTCCAGGAGT TGATCTGCATGGTGATGTTG 146 NM_001317043
FGF2 GCTGCTGGCTTCTAAGTGTG TACTGCCCAGTTCGTTTCAG 129 NM_019305
PDGFR α TTGAGCCCATTACTGTTGGA CCCATAGCTCCTGAGACCTT 148 NM_011058
FGFR2 GACGACACAGATAGCTCCGA CAGCGGAACTTCACAGTGTT 134 EF143338
CD31 CATTGGTTACCTCGGGAGTC GTCTTCACCCAGCCTTTCTC 104 NM_001107202
GAPDH ACAGCAACAGGGTGGTGGAC TTTGAGGGTGCAGCAACTT 252 NM_017008.4
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anti-rabbit IgG (H&L) (Alexa Fluor® 680) secondary
antibody (Life technologies; 1:20,000) at room temperature
for 1 h, and antibody-bound proteins were visualized
by fluorescence detection with a LI-COR odyssey
system.
Statistical analysis
All experiments were performed in triplicate and at
least three times and data analysed by an independent
two-tailed Student’s t test. A p value <0.05 was regarded
as statistically significant.
Fig. 1 Characterization of rBMSCs. Tri-lineage differentiation of rBMSC was performed in vitro. a Undifferentiated rBMSC. b Alizarin red S staining
of cells cultured for 14 days in osteogenic induction medium. c Alcian blue staining and toluidine blue staining of cells cultured for 14 days in
chondrogenic induction medium. d Oil red O staining of cells cultured for 7 days in adipogenic induction medium. Scale bar = 100 μm
Fig. 2 Gene delivery efficiency of P-GFP and MC-GFP DNA vectors. a Gel electrophoresis of P-GFP and MC-GFP plasmids following plasmid
purification and enzyme digestion. b Fluorescence microscopy of transfected HEK293T cells and rBMSCs with P-GFP and MC-GFP with a
range of plasmid concentrations and quantitation by flow cytometry of transfection efficiencies for (c) HEK293T cells and (d) rBMSCs. MC-GFP minicircle
vector expressing green fluorescent protein, P-GFP plasmid vector expressing green fluorescent protein, rBMSC rat bone marrow-derived
mesenchymal stem cell
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Results
Characterisation of rBMSCs
rBMSCs were isolated from adult Sprague–Dawley rats as
previously described [33], and plastic adherent rBMSCs
displayed typical fibroblastoid morphology (Fig. 1a) [40].
Tri-lineage differentiation of the rBMSCs was performed
in the appropriate media to osteoblasts as demonstrated
by Alzarin Red S staining of mineralised extracellular
matrix (Fig. 1b), to chondrocytes by Alcian Blue staining
of proteoglycans in three-dimensional pellet cultures
(Fig. 1c) and to adipocytes as shown by Oil Red O staining
of lipid vesicles (Fig. 1d).
Transfection of P-GFP and MC-GFP vectors
The GFP expressing minicircle vector (MC-GFP) was
produced from the parental plasmid (P-GFP) as de-
scribed in the manufacturer’s instructions (Systems
Bioscience). We observed an approximate 4-kb re-
duction in plasmid size following minicircle induc-
tion using L-arabinose (Fig. 2a). HEK293T cells and
rBMSCs were transfected with a range of plasmid
DNA concentrations (1 μg, 0.5 μg, 0.25 μg, 0.125 μg,
0.0625 μg,). After 48 h post-transfection, the cells
were visualised by fluorescence microscopy and analysed
by flow cytometry to estimate the percentage of GFP-
expressing (GFP+) cells (Fig. 2b). The optimum plasmid
DNA concentration for transection was 0.5 μg which
showed highest transfection efficiency for both P-GFP and
MC-GFP in both HEK293T (Fig. 2c) and rBMSC (Fig. 2d)
cell types.
Transfection of HEK293T cells with MC-GFP plasmid
resulted in a significantly higher number of GFP+ cells
((55.51 ± 3.3 %) compared to P-GFP (43.4 ± 4.9 %). A
similar trend was seen in rBMSCs, with MC-GFP result-
ing in a higher transfection efficiency (18.65 ± 1.05 %)
compared to P-GFP (15.21 ± 0.22 %).
Generation of eNOS minicircle vector
To generate an eNOS minicircle expression plasmid
vector, a codon optimized cDNA of human eNOS
(3633 bp) was synthesised (Geneart) and sub-cloned
into the parental plasmid P-GFP (CMV-MCS-EF1-
a
b c
Degraded by Sce-I 
endonuclease
minicircle DNA to be 
purified
Fig. 3 Construction of eNOS expressing minicircle DNA vector. a Schematic representation of in vitro production of MC-eNOS vector. b Confirmation
of cloning of eNOS gene into P-eNOS and MC-eNOS vectors by restriction enzyme digestion analysis. c P-eNOS and MC-eNOS gel electrophoresis
following minicircle plasmid purification. MC-eNOS minicircle vector expressing endothelial nitric oxide synthase, P-eNOS plasmid vector expressing
endothelial nitric oxide synthase
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GFP-SV40PolyA) (System Biosciences, Mountain View,
CA, USA) at the BamHI and SalI restriction sites in
the multiple cloning sites downstream to the CMV pro-
moter resulting in removal of the EF1α promoter and
eGFP coding sequence (Fig. 3a). The eNOS minicircle
vector was constructed as described above for the
MC-GFP vector. The cloning was confirmed by
double digestion of the parental plasmid encoding
eNOS (P-eNOS) with BamHI and SalI yielding a frag-
ment of ~3.7 kb (Fig. 3b). A reduction of the P-eNOS
vector size was also observed after the production of
MC-eNOS, to approximately 5 kb (Fig. 3c).
Transfection of P-eNOS and MC-eNOS vectors
Transfection of HEK293T cells with P-eNOS and MC-
eNOS was assessed by immunofluorescence staining
(Fig. 4a) and western blot analysis (Fig. 4b), using an
eNOS-specific monoclonal antibody (BD bioscience).
Nitric oxide production from transfected cells was
measured by the production of nitrite at 24 hand 48 h
post-transfection and in un-transfected HEK293T cells
(Fig. 4c). Both P-eNOS and MC-eNOS transfected
HEK293T cells showed significantly higher nitrite
accumulation in cell culture media (at both 24 h and
48 h) compared to P-GFP, MC-GFP transfected cells
and un-transfected HEK293T controls. At 24 h post-
transfection, HEK293T cells transfected with P-eNOS
and MC-eNOS resulted in 3.8 ± 0.2 μM and 4.46 ±
0.12 μM nitrite concentrations, respectively (Fig. 4c).
The NO production increased significantly at 48 h
post-transfection, resulting in 4.18 ± 0.12 μM and
5.06 ± 0.13 μM for P-eNOS and MC-eNOS, respectively.
Furthermore, detection of nitric oxide produced from
transfected cells was also confirmed by DAF-2DA staining
in live cells. Both P-eNOS and MC-eNOS transfected
HEK293T cells emitted a strong green fluorescence sig-
nal compared to no fluorescence in un-transfected
cells (Fig. 4d).
eNOS gene transfer to rBMSCs
Transfection of P-eNOS and MC-eNOS vectors into
rBMSCs was confirmed by immunostaining (Fig. 5a),
and western blot analysis (Fig. 5c) with an eNOS-
specific monoclonal antibody (BD bioscience). Both
Fig. 4 Expression of eNOS and NO production in transfected HEK293T cells. a Fluorescence microscopy of transfected HEK293T cells with
P-eNOS and MC-eNOS with 0.5 μg plasmid DNA. b Detection of eNOS protein expression in transfected HEK293T by western blot analysis.
c NO production in HEK293T cells at 24 h and 48 h post-transfection with P-eNOS and MC-eNOS plasmids using the griess assay, and
d detection of nitric oxide production in living cells following P-eNOS and MC-eNOS transfection and non-transfected control by DAF-2
fluorescence. *p < 0.05 and **p < 0.05 vs. MC-GFP, P-GFP, and HEK293T. MC-eNOS minicircle vector expressing endothelial nitric oxide
synthase, MC-GFP minicircle vector expressing green fluorescent protein, P-eNOS plasmid vector expressing endothelial nitric oxide
synthase, P-GFP plasmid vector expressing green fluorescent protein
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the assays confirmed that no endogenous eNOS ex-
pression was seen in un-transfected rBMSCs (Fig. 5a
and c). Significantly higher transfection efficiency for
MC-eNOS (21 ± 3 %) compared to P-eNOS (9 ± 3 %)
(Fig. 5b) was observed which resulted in higher NO
production for MC-eNOS transfected rBMSCs (1.93 ±
0.06 μM) than P-eNOS (1.78 ± 0.1 μM) (Fig. 5d)
compared to controls after 24 h of transfection. NO
production increased further in MC-eNOS transfected
rBMSCs (2.20 ± 0.08 μM) compared to P-eNOS at 48
h post-transfection (1.84 ± 0.1 μM) (Fig. 5d). NO syn-
thesis in transfected rBMSCs was also demonstrated
DAF-2DA staining in both P-eNOS and MC-eNOS
transfected rBMSCs (Fig. 5e).
eNOS gene delivery enhances in vitro capillary tubule
formation
Rat BMSCs were transfected with 0.5 μg P-eNOS,
MC-eNOS, P-GFP, and MC-GFP. Un-transfected
rBMSCs were used as a control. Transfected cells were
then plated on a 96-well cell culture plate coated with
an extracellular matrix (Geltrex). Both MC-eNOS
and P-eNOS transfected rBMSCs formed significantly
longer (14.66 ± 0.55 mm and 13.58 ± 0.68 mm, re-
spectively) tubules and a greater number of tubules
(56.33 ± 3.51 and 51 ± 4, respectively) compared to
rBMSCs transfected with P-GFP, MC-GFP and non-
transfected cells (Fig. 6).
To confirm that capillary-like tubule formation was
NO-mediated, eNOS transfected rBMSCs were treated
with 2 mM of the nitric oxide synthase inhibitor, L-
NG-nitroarginine methyl ester (L-NAME). L-NAME
treatment resulted in a significant impairment of the
tubule network, in terms of length (7.33 ± 1.03 mm
and 7.06 ± 0.88 mm for MC-eNOS and P-eNOS, re-
spectively) and tubule number (24 ± 4 and 24 ± 2 for
MC-eNOS and P-eNOS, respectively) compared to
untreated cells (Fig. 6).
Nitric oxide promotes in vitro cell migration
Using the scratch wound healing assay [37], migration of
eNOS transfected rBMSCs was assessed. Transfection of
Fig. 5 Expression of eNOS and NO production in transfected rBMSCs. a Fluorescence microscopy of transfected of rBMSCs with P-eNOS and
MC-eNOS with 0.5 μg plasmid DNA. b Transfection efficiency of MC-eNOS and P-eNOS. c Detection of eNOS protein expression in transfected
rBMSC by western blot analysis. d NO production in rBMSC cells at 24 hand 48 h post-transfection with P-eNOS and MC-eNOS plasmids using
the griess assay. e Detection of nitric oxide production in living cells following P-eNOS and MC-eNOS transfection by DAF-2 fluorescence.
#p < 0.05 vs. P-eNOS; *p < 0.05 and **p < 0.05 vs. MC-GFP, P-GFP, and rBMSC. MC-eNOS minicircle vector expressing endothelial nitric oxide
synthase, MC-GFP minicircle vector expressing green fluorescent protein, P-eNOS plasmid vector expressing endothelial nitric oxide synthase, P-GFP
plasmid vector expressing green fluorescent protein, rBMSC rat bone marrow-derived mesenchymal stem cell
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P-eNOS and MC-eNOS enhanced cell migration com-
pared to P-GFP, MC-GFP and un-transfected rBMSCs
(MC-eNOS, 44.05 ± 0.81 %; P-eNOS, 43.13 ± 3.45 %;
MC-GFP, 10.43 ± 2.63 %; P-GFP, 11.39 ± 3.03 %; and
rMSC, 9.46 ± 4.13 %) (Fig. 7a and c). However, cell mi-
gration rates between P-eNOS and MC-eNOS were not
significantly different. Inhibition of NO production by
treatment with 2 mM L-NAME significantly dimin-
ished the cell migration rates of both MC-eNOS and
P-eNOS transfected cells (12.18 ± 1.67 % and 15.59 ±
4.69 %, respectively) (Fig. 7a and c). Cell migration
rates were not significantly different among MC-GFP,
P-GFP and un-transfected cells (Fig. 7a and c). A simi-
lar phenomenon was observed with HEK293T cells
(Fig. 7b and d).
MC-eNOS gene transfer to rBMSCs induces endothelial
CD31 gene expression
We found a significant increase in CD31 mRNA
expression by 0.42-fold in P-eNOS transfected cells
compared to P-GFP, MC-GFP and un-transfected con-
trol, suggesting that eNOS gene transfer may promote
endothelial differentiation of rBMSCs (Fig. 8). Inter-
estingly, minicircle-mediated eNOS (MC-eNOS) gene
transfer showed a highly significant increase in CD31
mRNA expression by 1.8-fold compared to P-eNOS,
P-GFP, MC-GFP, and un-transfected control (Fig. 8).
Treatment with 2 mM L-NAME abolished the CD31
expression (Fig. 8), suggesting that expression of endo-
thelial CD31 in rBMSCs through eNOS gene transfer is
NO-mediated.
Fig. 6 In vitro tubule formation in eNOS transfected rBMSCs. a Capillary tubule formation in rBMSCs transfected with P-eNOS and MC-eNOS and
cytoskeletal staining by Phalloidin TRITC; treatment with the NO inhibitor L-NAME reduces capillary formation. b Quantitation of tubule number.
c Measurement of tubule length. *p < 0.05 and **p < 0.05 vs. MC-eNOS (L-NAME), P-eNOS (L-NAME), MC-GFP, P-GFP, and rBMSC. L-NAME,
L-NG-nitroarginine methyl ester, MC-eNOS minicircle vector expressing endothelial nitric oxide synthase, MC-GFP minicircle vector expressing
green fluorescent protein, P-eNOS plasmid vector expressing endothelial nitric oxide synthase, P-GFP plasmid vector expressing green fluorescent protein,
rBMSC rat bone marrow-derived mesenchymal stem cell
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NO modulates VEGF-A/PDGFR and FGF2/FGFR2 signalling
pathways in eNOS transfected rBMSCs
Expression of two key genes, VEGF-A and FGF2, which
are involved in angiogenesis and cell migration were ex-
amined by quantitative real time PCR. Upregulation of
both VEGF-A by 1.19-fold and 1.0-fold in MC-eNOS
and P-eNOS modified rBMSCs, respectively (Fig. 9a),
and FGF2 by 1.08-fold in MC-eNOS and 0.74-fold in P-
eNOS delivered rBMSCs (Fig. 9b), compared to P-GFP,
MC-GFP delivered rBMSCs and un-transfected rBMSCs.
Treatment with 2 mM L-NAME reduced both VEGF-A
(Fig. 9a) and FGF2 (Fig. 9b) expression in P-eNOS and
MC-eNOS transfected cells. Furthermore, delivery of P-
GFP and MC-GFP did not affect the VEGF-A and FGF2
expression compared to control rBMSCs (Fig. 9a and
9b). Next, we examined the effect of NO on the expres-
sion of PDGFRα and FGFR2 receptors as they are corre-
sponding receptors of VEGF-A and FGF2. Expression of
PDGFRα was increased by 1.82-fold and 1.56-fold in
MC-eNOS and P-eNOS transfected rBMSCs, respect-
ively (Fig. 9c), and FGFR2 receptor expression was
increased by 1.46-fold in MC-eNOS and 1.14-fold in P-
eNOS delivered rBMSCs (Fig. 9d), compared to P-GFP,
MC-GFP delivered rBMSCs and un-transfected rBMSCs.
Treatment with 2 mM L-NAME abolished both the
PDGFRα (Fig. 9c) and FGFR2 (Fig. 9d) expression in
P-eNOS and MC-eNOS transfected cells. Furthermore,
neither PDGFRα nor FGFR2 receptor expression were af-
fected by the delivery of P-GFP and MC-GFP compared
to control rBMSCs (Fig. 9c and d).
Discussion
Minicircle vectors are supercoiled DNA molecules that
are devoid of bacterial backbone sequences such as a bac-
terial origin of replication, antibiotic resistance gene and
CpG motifs [41], and primarily consist of a eukaryotic ex-
pression cassette [6]. Compared to conventional plasmid
DNA, minicircle vectors benefit from higher transfection
efficiencies and longer transgene expression, possibly
attributed to a lower activation of gene silencing
mechanisms [42].
Fig. 7 In vitro cell scratch assay of eNOS transfected rBMSCs and HEK293T cells. Phase-contrast microscopy images of transfected and control cell
migration at (a) 0 and 1 h for rBMSCs and (b) 0 and 17 h for HEK293T post-cell scratch and effect of the NO inhibitor L-NAME. Percentage of cell
migration (c) at 1 h for rBMSCs and (d) 17 h for HEK293T post-cell scratch and effect of the NO inhibitor L-NAME. *p < 0.05 and **p < 0.05 vs.
MC-eNOS (L-NAME), P-eNOS (L-NAME), MC-GFP, P-GFP, rBMSC and HEK293T. L-NAME, L-NG-nitroarginine methyl ester, MC-eNOS minicircle
vector expressing endothelial nitric oxide synthase, MC-GFP minicircle vector expressing green fluorescent protein, P-eNOS plasmid vector
expressing endothelial nitric oxide synthase, P-GFP plasmid vector expressing green fluorescent protein, rBMSC rat bone marrow-derived
mesenchymal stem cell
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In this study, minicircles expressing GFP exhibited
higher in vitro gene transfer efficiency than the parental
plasmid to both HEK293T cells and rBMSCs (Fig. 3). As
expected transfection efficiency was higher in the trans-
formed cell line (HEK293T) compared to primary
rBMSCs. eNOS expressing minicircles also showed
higher gene transfer efficiency than P-eNOS (Fig. 5b).
This higher gene transfer efficiency may also account for
the significantly increased level of NO synthesis by MC-
eNOS compared to P-eNOS (Figs. 4 and 5). We rea-
soned that this high level of NO synthesis from MC-
eNOS transfected rBMSCs may be attributed to the re-
moval of other plasmid sequences, which can affect gene
expression [42], and the smaller size of the minicircle
may also provide a more efficient route to the nucleus
for transcription. This process involves several steps,
including cellular entry of DNA through the cell
membrane, DNA diffusion into the cytoplasm, and DNA
entry to the nucleus [43]. Importantly, the DNA diffu-
sion step depends on the physicochemical properties of
DNA such as its diffusion coefficient, which is inversely
proportional to its molecular weight [44, 45]. Endocyto-
sis is a major route for entry of DNA–cationic lipid
complexes through the cell membrane in vitro [46]
which takes place following specific interactions between
DNA and caveolae [47]. This mechanism is also limited
by particle size, where larger DNA–cationic lipid com-
plexes are not efficiently taken up by the endocytosis
[47]. DNA uptake and transfer to the nucleus via the nu-
clear membrane results in successful gene transfer [48].
Minicircle plasmid vector may overcome these cellular
obstacles more efficiently and, combined with a lack of
bacterial backbone sequences, reduced promoter methy-
lation [49] may also contribute to the higher levels of
gene transfer compared to larger parental plasmids.
Angiogenesis is a complex process involving endothe-
lial cell proliferation and migration, remodelling of
extracellular matrix, and tubular structure formation.
These processes are tightly regulated by the actions of
angiogenic cytokines such as VEGF-A and FGF [31].
Angiogenesis also requires endothelial cell-to-cell, and
cell-to-matrix interactions, which are mediated by vari-
ous cell adhesion molecules [50]. eNOS plays a key role
in angiogenesis mediated by substance P, a potent
endothelium-dependent vasodilator (NO releaser) [51].
It has also been demonstrated that eNOS-KO (knock-
out) mice show impaired angiogenesis [52].
NO has been shown to play an important role in
angiogenesis both in vitro and in vivo, and furthermore
NO also contributes to endothelial cell migration in
vitro [52]. We found that eNOS gene transfer by MC
vector remarkably promoted endothelial-specific CD31
gene expression (Fig. 8), contributing to the capillary-
like tubule network formation by rBMSCs (Fig. 6) and
enhanced cell motility as evident by in vitro wound heal-
ing assay (Fig. 7). Noteworthy, in these assays, CD31
mRNA expression, tubule formation and cell migration
in transfected cells were significantly abrogated by L-
NAME treatment, suggesting NO plays a major role in
enhancing endothelial characteristics in rBMSCs. Col-
lectively, our data may suggest that MC-mediated eNOS
gene transfer may contribute to the reprogramming of
adults stem cells into endothelial cells, which may be
used in cell therapy applications involving vascular
repair. Interestingly, Gomes and co-workers demon-
strated that MSCs from S-nitrosoglutathione reductase
(GSNOR)-deficient mice, where NO is produced mainly
from iNOS (NOS2) rather than eNOS, exhibited attenu-
ated vasculogenesis both in vitro and in vivo [13]. Fur-
thermore, they revealed that pharmacological inhibition
of NO in GSNOR−/− MSCs, or genetic reduction of NO
Fig. 8 Nitric oxide promotes CD31 gene expression in eNOS
transfected rBMSCs. Relative mRNA expression of endothelial-specific
CD31 was upregulated in MC-eNOS and P-eNOS transfected rBMSCs
as assessed by quantitative real time PCR. *p < 0.05 and **p < 0.05 vs.
MC-eNOS (L-NAME), P-eNOS (L-NAME), MC-GFP, P-GFP, and rBMSC.
L-NAME, L-NG-nitroarginine methyl ester, MC-eNOS minicircle vector
expressing endothelial nitric oxide synthase, MC-GFP minicircle vector
expressing green fluorescent protein, P-eNOS plasmid vector expressing
endothelial nitric oxide synthase, P-GFP plasmid vector expressing green
fluorescent protein, rBMSC rat bone marrow-derived mesenchymal
stem cell
Bandara et al. Stem Cell Research & Therapy  (2016) 7:48 Page 11 of 15
production in the NOS2−/−, enhanced vasculogenesis
by MSCs than that for HUVECs, where NO synthesis
is driven by eNOS enhanced vascular tube formation.
MSCs have not been shown to express endogenous
eNOS, unlike endothelial cells [53], and have been
shown to participate in pro-angiogenic signalling [54].
Additionally, eNOS plays an important role in endo-
thelial cell-mediated postnatal angiogenesis and vascu-
lar tone [55, 56].
NO may contribute to angiogenesis through VEGF
and FGF signalling through an angiogenic switch which
is preceded by a local increase in VEGF-A and FGF [31].
Fig. 9 Nitric oxide modulates VEGF-A/PDGFRα and FGF2/FGFR2 gene expression. Relative mRNA expression of the angiogenesis-related genes
(a) VEGF-A and (b) FGF2 and their corresponding receptors, c PDGFRα and d FGFR2, were upregulated in MC-eNOS and P-eNOS transfected
rBMSCs as assessed by quantitative real time PCR. *p < 0.05 and **p < 0.05 vs. MC-eNOS (L-NAME), P-eNOS (L-NAME), MC-GFP, P-GFP, and rBMSC.
FGF(R) fibroblast growth factor (receptor), L-NAME, L-NG-nitroarginine methyl ester, MC-eNOS minicircle vector expressing endothelial nitric oxide
synthase, MC-GFP minicircle vector expressing green fluorescent protein, PDGFR platelet-derived growth factor receptor, P-eNOS plasmid vector
expressing endothelial nitric oxide synthase, P-GFP plasmid vector expressing green fluorescent protein, rBMSC rat bone marrow-derived
mesenchymal stem cell, VEGF vascular endothelial growth factor
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Nitric oxide can mediate the production of VEGF-A in
human adipose-derived stem cells [57] and NO and
FGF2 have also been shown to enhance angiogenesis in
mouse embryonic stem cells [58]. Furthermore, FGF2
has been shown to induce eNOS expression [32]. Our
data proposes that NO signalling through VEGF-A/
PDGFRα and FGF2/FGFR2 pathways may directly pro-
mote rBMSC vasculogenesis (Fig. 9). We showed that
eNOS transfected rBMSCs express increased levels of
VEGF-A and FGF2 (Fig. 9) and their corresponding re-
ceptors PDGFRα, and FGFR2, respectively (Fig. 9). It is
noteworthy that MC-eNOS vector transfection was asso-
ciated with a significantly higher FGF2 expression com-
pared to the P-eNOS vector. Interestingly, treatment
with L-NAME diminished the VEGF-A, PDGFRα, FGF2
and FGFR2 expression levels (Fig. 9) which were ob-
served as being linked to impaired capillary tube-like
network formation (Fig. 6). It has been shown that
VEGF-A contributes to differentiation of MSCs to
endothelial-like cells when co-cultured with endothelial
cells expressing eNOS and this process is inhibited by
VEGF-A antisera [59].
Angiogenesis is also associated with endothelial cell
migration and proliferation [60]. Our results show
that eNOS gene transfer into HEK293T and rBMSCs
(Fig. 7) can increase cell motility compared to controls,
and the effect is diminished by L-NAME treatment,
suggesting that NO plays a role in regulating rBMSC cell
migration (Fig. 7) which has been previously demon-
strated for endothelial cell migration [61]. Together, these
findings show that genetic manipulation of MSCs to en-
hance bioavailable NO may upregulate VEGF-A/PDGFRα
and FGF2/FGFR2 signalling pathways to promote angio-
genesis (Fig. 10).
Conclusions
In summary, this study demonstrates that NO derived
from a minicircle DNA vector expressing eNOS exerts
a positive effect on rBMSCs by promoting in vitro ca-
pillary tubule formation and cell migration and signifi-
cant increases in angiogenesis-related gene expression.
Use of MC-eNOS-based vectors may represent an
efficient approach to gene therapy applications where
enhancing NO bioavailability is beneficial.
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